Overview

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Status:
Completed

Trial end date:
2020-03-20

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well netupitant and palonosetron hydrochloride work in preventing chemotherapy induced nausea and vomiting in patients with cancer undergoing BEAM conditioning regimen before stem cell transplant. Chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan (BEAM), makes people feel sick to their stomach and causes vomiting. Netupitant and palonosetron hydrochloride may reduce the nausea and vomiting caused by the BEAM treatment.

Phase:

Phase 2

Details

Lead Sponsor:

OHSU Knight Cancer Institute

Collaborators:

Helsinn Therapeutics (U.S.), Inc
National Cancer Institute (NCI)
Oregon Health and Science University

Treatments:

Palonosetron